Publications by authors named "E L Moshier"

Purpose: There is limited data on the use of low dose tamoxifen (LDT) for chemoprevention since its introduction in 2019. This study sought to determine the rate of LDT uptake at our institution and describe factors associated with its use.

Methods: We performed a retrospective chart review of women diagnosed with ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), and/or atypical hyperplasia from 2019 to 2021.

View Article and Find Full Text PDF

Purpose: The study's goal was to evaluate the impact of a Radiation Oncologist (RO)-Radiation Therapist (RTT) mentorship on image approval rates for a breast population undergoing radiation therapy in a high-volume practice. The mentorship was undertaken within a large health system in partial fulfillment of the Expert Practice Module for a Masters (MSc) in Advanced Practice Radiotherapy and Oncology.

Methods: Images were retrieved from the MOSAIQ EMR on breast diagnostic code.

View Article and Find Full Text PDF
Article Synopsis
  • First-degree relatives of multiple myeloma patients have a higher risk for the disease, yet the role of genetic variants in hereditary cancer genes remains unclear.
  • A study analyzed germline exomes from nearly 1,700 multiple myeloma patients, identifying pathogenic variants in about 8.6-11.5% of cases, particularly in DNA repair genes like BRCA1 and BRCA2.
  • The findings suggest that around 10% of multiple myeloma patients may have an undiagnosed cancer predisposition syndrome, indicating the importance of considering genetic testing for younger patients or those with a family cancer history to inform treatment options.
View Article and Find Full Text PDF

Autologous stem cell transplantation is a standard treatment strategy for patients with multiple myeloma that requires effective mobilization and apheresis of peripheral blood progenitor cells; however, in the current era of novel myeloma induction therapies, the optimal mobilization regimen to enhance stem cell yield while limiting toxicity and resource utilization remains unknown. In this multicenter retrospective study, we assessed apheresis and transplant outcomes in myeloma patients mobilized with granulocyte colony stimulating factor (G-CSF) alone (n = 62), G-CSF with chemotherapy (n = 43), or G-CSF with the CXCR4 antagonist plerixafor (n = 417). Compared to patients treated with G-CSF alone, the plerixafor group required significantly fewer median apheresis sessions (1 vs 2, p = 0.

View Article and Find Full Text PDF